SEC Filing Analysis: NEOGEN CORP (NEOG)

Executive Summary

• Trading Significance: Low
• Key Takeaway: A director, Andrea F. Wainer, was awarded a standard compensation package consisting of Restricted Stock Units (RSUs) and stock options, a routine event with minimal market impact.
• Market Impact: The grant is too small relative to the company's market capitalization to have a material impact on the stock price or shareholder value.

Company Information

Field	Value
Company	NEOGEN CORP
Ticker Symbol	NEOG
CIK	0000711377
Industry	In Vitro & In Vivo Diagnostic Substances

Insider Information

Field	Value
Name	Wainer Andrea F
CIK	0001778070
Title/Position	null
Relationship	Director

Transaction Details

This filing reports two grants: a non-derivative award of common stock (RSUs) and a derivative award of stock options.

Non-Derivative (RSU Grant)

Field	Value
Form Type	4
Transaction Date	2025-10-23
Transaction Code	A (Award)
Security Type	Common Stock
Shares Involved	19,769
Price Per Share	$6.07
Total Value	$120,000.83
Shares Owned After	19,769
Ownership Type	Direct

Derivative (Option Grant)

Field	Value
Security Type	Common Stock (Right to Buy)
Shares Involved	50,814
Exercise Price	$6.07
Expiration Date	2035-10-23
Total Value	$0 (Price paid for grant)
Shares Owned After	50,814 (Options)

Financial Impact Assessment

Transaction Materiality

Analysis combines both the RSU and underlying option grants for a comprehensive view.

Metric	Value
Total Shares Granted	70,583 (19,769 RSUs + 50,814 Options)
% of Shares Outstanding	0.033%
RSU Grant Value	$120,001
% of Market Cap	0.009%
Post-Transaction Ownership	19,769 common shares (0.009% of outstanding)
Materiality Assessment	Low

Impact Evaluation

• Market Cap Context: The reported RSU grant value of $120k is negligible against NEOGEN's $1.35 billion market capitalization. Even when estimating the total potential value, the transaction remains immaterial.
• Ownership Concentration: This grant establishes the director's initial direct holding in the company's common stock. The resulting ownership of 0.009% is minimal.
• Dilution Impact: The 70,583 total shares granted (RSUs and options) represent approximately 0.033% of the total shares outstanding. This is a very low level of dilution and is a standard cost of director compensation.
• Transaction Significance: The transaction's significance is low. It is an initial compensation grant for a director, not an open-market purchase reflecting new bullish sentiment. The size is well below the thresholds for moderate or high significance.

Market Impact Analysis

Stock Impact Prediction

• Direction: Neutral
• Reasoning: Equity grants to directors are routine and expected by the market. They do not signal new information about the company's future prospects and are too small to affect supply/demand dynamics for the stock.

Volume & Sentiment

• Expected Volume Impact: None. The shares are awarded, not traded on the open market.
• Sentiment Indicator: Neutral. This is a standard corporate governance action, not an investment decision by the insider.

Investment Insights

Positive Market Indicators

• Aligning director interests with shareholders through equity ownership is a positive governance practice.

Risk Factors

• No immediate risk factors are apparent from this routine filing.

Key Takeaways

1. A director received a standard equity compensation package.
2. The total value and share count are immaterial relative to the company's market cap and shares outstanding.
3. The transaction represents a negligible dilution impact (0.033%) on existing shareholders.

Additional Context

Transaction Notes

• Vesting Schedule: The footnote indicates that both the options and RSUs vest in equal annual installments over three years, which is a typical retention mechanism.
• Transaction Code 'A': The 'A' code confirms this was an award/grant, not an open-market purchase of shares with the insider's own capital.